Long-term safety of JRM-001 stem cells in children with single ventricle
Follows children with single ventricle heart disease after JRM-001 stem cells.
Key facts
- Who runs it
- Metcela Inc.
- Where
- Japan1 site in 1 countryChoose a country to see its sites
- Trial code
- Registry title
- Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease
- Status
- Recruiting
- People taking part
- 40 people, planned
- Started
- 1 Sept 2026
- Expected to end
- 28 Feb 2030
- Type of study
- Observational, 2 groups
- Record updated
- 20 October 2026
Who can take part
AI summary
From the trial's eligibility criteria. Machine-read from the registry text on this page, so it can be wrong. The registry text below and the trial team decide who can take part.
The trial is looking for children with congenital heart disease (single ventricle) who took part in the earlier JRM-001 study. It follows their safety for one year.
- Sex
- All sexes can join.
- Disease stage
- Single ventricle heart, including hypoplastic left heart syndrome (HLHS), after reconstructive heart surgery.
- Earlier treatment
- People must have taken part in the earlier JRM-001 study. They either received JRM-001 after a heart catheter test, or had the catheter test only.
Main reasons for not taking part
- Hard to visit the trial site
- Hard to get medical information from the hospital the patient moved to
The registry criteria, word for word
Show all 5 criteriaShow less
Who can take part
- Patients who participated in "Efficacy and safety study of autologous cardiac stem cells (JRM-001) treated after reconstructive surgery in pediatric patients with congenital heart disease" and meet the following criteria
- JRM-001 administration group: received JRM-001 investigational product after catheter examination
- Non-administered group: underwent cardiac catheter examiniation only
Who cannot take part
- Patients who is difficult to visit the clinical trial site
- Patients who is difficult to obtain the provision of medical information from clinical institute to which the patient is transferred
This trial has no sites in United States.
It has sites in one country. Choose a country to see its sites.
About the trial
What the trial wants to find out
The objective of this observational study is to investigate the long-term safety of autologous cardiac stem cells (JRM-001) administered to patients with single ventricle physiology. This study will conduct a one-year safety follow-up of participants in "Efficacy and safety study of autologous cardiac stem cells (JRM-001) treated after reconstructive surgery in pediatric patients with congenital heart disease".
The 2 groups in the trial
- JRM-001 administration Group
Patients who were administered JRM-001 in the study "Efficacy and safety study of autologous cardiac stem cells (JRM-001) treated after reconstructive surgery in pediatric patients with congenital heart disease".
- Non-administeration Group
Patients who were not administered JRM-001 in the study "Efficacy and safety study of autologous cardiac stem cells (JRM-001) treated after reconstructive surgery in pediatric patients with congenital heart disease".
Questions to ask the study team
- How often do I need to come in, and for how long each time?
- Are travel costs paid?
- Can I keep my own doctor?
- What happens if I want to stop?
Contact the study team: see the registry record → Contacts and Locations
Print a page for my doctorData and sources
- Registry record
- Listed on ClinicalTrials.gov.How to verify a trial in the registry
- Official title
- Long-term Safety Study Following to JRM-001 Treatment in Pediatric Patients With Congenital Heart Disease
- Plain-language title
- Long-term safety of JRM-001 stem cells in children with single ventricleGenerated from the registry record. The registry title is the official one.
- AI summary
- From the trial's eligibility criteria. Read by machine on 14 November 2026.
- Record updated
- 20 October 2026